tbuckley/cabot-search huggingface dataset:
Severe early‐onset manifestations of pseudoxanthoma elasticum resulting from the cumulative effects of several deleterious mutations in<i>ENPP1</i>,<i>ABCC6</i>and<i>HBB</i>: transient improvement in ectopic calcification with sodium thiosulfate
Authors: L. Omarjee, Y. Nitschke, S. Verschuere, E. Bourrat, M.‐D. Vignon, N. Navasiolava, G. Leftheriotis, G. Kauffenstein, F. Rutsch, O.M. Vanakker, L. Martin
Journal: British Journal of Dermatology (2019)

Pseudoxanthoma elasticum (PXE) is a rare disorder characterized by fragmentation and progressive calcification of elastic fibres in connective tissues. Overlap has been reported between the inherited PXE phenotype associated with ENPP1, ABCC6 or NT5E mutations and acquired PXE clinical manifestations associated with haemoglobinopathies induced by HBB mutations. No treatment is currently available for PXE. A young boy presented with severe early-onset systemic calcifications occurring in the skin as elastosis perforans serpiginosa (EPS) and in the arteries, causing mesenteric and limb ischaemia. Analyses revealed deleterious ABCC6, ENPP1 and HBB mutations. The diagnosis of severe PXE was retained and we have coined the term 'PXE+ syndrome' to describe the cumulative effects of the various mutations in this uncommon phenotype. Given the severity, rapid progression and a potentially fatal prognosis, intravenous sodium thiosulfate (STS) was initiated at 25 g three times weekly for 6 months. Numerous side-effects prompted dosage adjustment to 10 g intravenously daily. Treatment efficacy was evaluated at 6 months. Asthaenia, anorexia and pre-/postprandial pain had subsided, entailing weight gain. Abdominal EPS had diminished. Calcific stenosis of the coeliac and mesenteric arteries was no longer detectable on arterial ultrasonography. Follow-up revealed only transient efficacy of STS. Discontinuation of treatment to evaluate the persistence of effects resulted in relapse of the initial symptomatology after 4 months. STS efficacy is conceivably due to strong antioxidant properties and chelation of calcium to form soluble calcium thiosulfate complexes. This case is suggestive of PXE+ syndrome for which STS may represent potential treatment in severe cases. What's already known about this topic? Generalized arterial calcification of infancy may occur in association with ABCC6 mutations and pseudoxanthoma elasticum (PXE) can be linked to ENPP1 mutations. A PXE-like phenotype has also been reported in a subset of patients with inherited haemoglobinopathies, namely sickle cell disease or β-thalassaemia, related to HBB mutations. To date, there is still no cure for PXE. What does this study add? We report a severe case of PXE resulting from the cumulative effects of several deleterious mutations in ENPP1, ABCC6 and HBB. We suggest the term 'PXE+ syndrome' to describe such patients. Sodium thiosulfate therapy could represent a potential option in severe cases of PXE+ syndrome.
Molecular Biology and Evolution of Cancer: From Discovery to Action
Authors: Jason A Somarelli, Heather Gardner, Vincent L Cannataro, Ella F Gunady, Amy M Boddy, Norman A Johnson, Jeffrey Nicholas Fisk, Stephen G Gaffney, Jeffrey H Chuang, Sheng Li, Francesca D Ciccarelli, Anna R Panchenko, Kate Megquier, Sudhir Kumar, Alex Dornburg, James DeGregori, Jeffrey P Townsend
Journal: Molecular Biology and Evolution (2019)

Abstract Cancer progression is an evolutionary process. During this process, evolving cancer cell populations encounter restrictive ecological niches within the body, such as the primary tumor, circulatory system, and diverse metastatic sites. Efforts to prevent or delay cancer evolution—and progression—require a deep understanding of the underlying molecular evolutionary processes. Herein we discuss a suite of concepts and tools from evolutionary and ecological theory that can inform cancer biology in new and meaningful ways. We also highlight current challenges to applying these concepts, and propose ways in which incorporating these concepts could identify new therapeutic modes and vulnerabilities in cancer.
P1.14-20 Tarloxotinib as a Novel Therapeutic Strategy for Oncogenic Alterations Across the ErbB Family of Receptors
Authors: A. Estrada-Bernal, Z. Du, A. Le, A. Patterson, J. Smaill, V. Tirunagaru, A. Vellanki, R. Doebele, C. Lovly
Journal: Journal of Thoracic Oncology (2019)
Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia
Authors: Michael J. Koren, Marc S. Sabatine, Robert P. Giugliano, Gisle Langslet, Stephen D. Wiviott, Andrea Ruzza, Yuhui Ma, Andrew W. Hamer, Scott M. Wasserman, Frederick J. Raal
Journal: Journal of the American College of Cardiology (2019)

Evolocumab and other anti-PCSK9 antibodies reduced adverse cardiovascular outcomes in clinical trials of high-risk patients over <3 years median treatment duration. The OSLER-1 trial (Open Label Study of Long Term Evaluation Against LDL-C Trial) evaluated longer-term effects of evolocumab during open-label hypercholesterolemia treatment for up to 5 years. Patients randomized to standard of care (SOC) or evolocumab 420 mg monthly (evolocumab + SOC) for year 1. After year 1, patients could enter the all-evolocumab period and receive evolocumab + SOC for an additional 4 years. The authors analyzed the persistence of lipid effects and exposure-dependent safety focusing on yearly rates of adverse events (AEs) and anti-drug antibodies over 4.951 patient-years of observation. A total of 1,255 patients (safety analysis population) randomized into the year 1 SOC-controlled period and received ≥1 evolocumab dose (mean ± SD age 57 ± 12 years; 53% female). A total of 1,151 patients (efficacy analysis population) progressed to the all-evolocumab period (year 2 and beyond). Evolocumab + SOC persistently lowered mean ± SE low-density lipoprotein cholesterol (LDL-C) by 56% ± 0.6% (n = 1,071), 57% ± 0.8% (n = 1,001), 56% ± 0.8% (n = 943), and 56% ± 0.8% (n = 803) after approximately 2, 3, 4, and 5 years, respectively, from randomization. Mean baseline LDL-C decreased from 140 to 61 mg/dl on treatment. Yearly serious AE rates during evolocumab + SOC ranged from 6.9% to 7.9%, comparable to the 6.8% rate in SOC patients during year 1. Evolocumab discontinuation due to AEs occurred in 5.7% of patients. Two SOC and 2 evolocumab + SOC patients developed new, transient, binding anti-drug antibodies; no neutralizing antibodies were observed. The OSLER-1 trial demonstrated consistently excellent LDL-C–lowering efficacy, tolerance, and safety of evolocumab, with no neutralizing antibodies detected, throughout the longest-duration study of a PCSK9 inhibitor reported to date. (Open Label Study of Long Term Evaluation Against LDL-C Trial [OSLER-1]; NCT01439880)
P1.01-106 Clinical Features and Tumor Immune Microenvironment Related to Acquired Resistance to EGFR-TKI in NSCLC Patients with EGFR Mutation
Authors: P. Zhang, L. Tu, R. Liu, X. Xu, Z. Bao, P. Xu, J. Wang, H. Li, J. Zhou, Y. Wang
Journal: Journal of Thoracic Oncology (2019)
Clinical Ethics Expertise as the Ability to Co-Create Normative Recommendations by Guiding a Dialogical Process of Moral Learning
Authors: Giulia Inguaggiato, Suzanne Metselaar, Guy Widdershoven, Bert Molewijk
Journal: The American Journal of Bioethics (2019)

Brummett and Salter contribute to much-needed clarity on the (relation between the) different views on the nature of clinical ethics expertise by presenting a sophisticated taxonomy. At the foundat...
National Prevalence of Pain Among Children and Adolescents With Autism Spectrum Disorders
Authors: Daniel G. Whitney, Danielle N. Shapiro
Journal: JAMA Pediatrics (2019)

Pain is a leading contributor to the global morbidity and disability burden. 1 Pediatric pain is especially problematic, as it may impede healthful development into and throughout adulthood. 2For children with autism spectrum disorders (ASD), pain is a highly understudied area, perhaps owing to the misguided historical impression that children with ASD have lower pain sensitivity. 3However, recent evidence has contradicted this perspective 4 and indicates that pain may be implicated in pathogenesis of poor health outcomes in children with ASD. 5 Therefore, this study sought to provide recent national estimates of the prevalence of pain among children and adolescents with ASD.Methods | Data came from the 2016-2017 National Survey of Children's Health, a nationally representative, parent-proxy survey of US children. 6The overall weighted response rate was 40.7% for 2016 and 37.4% for 2017.
MA03.06 Efficacy Results of Selective AXL Inhibitor Bemcentinib with Pembrolizumab Following Chemotherapy in Patients with NSCLC
Authors: E. Felip, P. Brunsvig, Å. Helland, N. Viñolas, S. Aix, E. Carcereny, M. Dómine Gomez, J.M. Trigo Perez, E. Arriola, R. Garcia Campelo, J. Spicer, J. Thompson, A.L. Ortega Granados, R. Holt, D. Smethurst, J. Lorens, M. Shoaib, A. Siddiqui, J. Schoelermann, K. Lorens, E. Schmidt, M.J. Chisamore, M. Krebs
Journal: Journal of Thoracic Oncology (2019)
P2.06-09 Drop the Scalpel: Long-Term Survival in Mesothelioma Without Extrapleural Pneumonectomy or Pleurectomy Decortication
Authors: G. Woodard, J. Crockard, A. Anand, V. Ding, K. Jones, M. Gubens, C. Blakely, T. Jahan, D. Jablons
Journal: Journal of Thoracic Oncology (2019)
EP1.18-12 The Neutrophil and Platelet to Lymphocyte Ratios and Glasgow Prognostic Score as a Predictor for Relapse After Stereotactic Radiation for Lung Cancer
Authors: J. Berg, M. Lindberg, M. Bengtson, O.T. Brustugun, Å. Helland
Journal: Journal of Thoracic Oncology (2019)
P1.01-75 Prognostic Impact of Neutrophil-to-Lymphocyte Ratio (NLR) for Advanced Non-Small Cell Lung Cancer
Authors: M. Ishihara, R. Ochiai, T. Haruyama, Y. Tagami, T. Sakamoto, S. Tanzawa, T. Honda, S. Ota, Y. Ichikawa, K. Watanabe, N. Seki
Journal: Journal of Thoracic Oncology (2019)
EP1.01-80 Progressive Disease with T790M Mutation vs Non-T790M Mutation in EGFR Positive Patients Treated with Tyrosine Kinase Inhibitors
Authors: D. Reis, N. China, M. Dias, D. Coutinho, E. Silva, S. Campainha, T. Costa, S. Conde, L. Cirnes, A. Barroso
Journal: Journal of Thoracic Oncology (2019)
MA12.06 Patient-Derived Organotypic Tumor Spheroids (PDOTS) Facilitate Therapeutic Screening for Malignant Pleural Mesothelioma
Authors: D. Larios, E. Ivanova, A. Aref, A. Portell, A. De Rienzo, D. Barbie, C. Paweletz, R. Bueno
Journal: Journal of Thoracic Oncology (2019)
P1.15-10 Trabectedin Has Limited Clinical Activity in Pretreated Patients with Pleural Mesothelioma
Authors: G. Pasquini, L. Petrini, R. Castellana, I. Pecora, C. Vivaldi, M. Lucchesi, A. Chella, A. Falcone
Journal: Journal of Thoracic Oncology (2019)
EP1.03-30 FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC
Authors: S. Richtmann, D. Wilkens, A. Warth, F. Lasitschka, H. Winter, P. Christopoulos, F. Herth, T. Muley, M. Meister, M. Schneider
Journal: Journal of Thoracic Oncology (2019)
P1.04-45 Immune-Oncology Gene Expression Profiles Allow Lung Cancer Patients’ Stratification and Identification of Responders to Immunotherapy
Authors: F. Tabbò, L. Annaratone, A. Nocifora, C. Vignale, S. Carnio, J. Metovic, F. Veneziano, S. Scodes, A. Russo, T. Franchina, C. Sini, S. Coco, P. Garlatti, S. Vieri, V. Adamo, S. Boccardo, F. Grossi, F. Cappuzzo, M. Papotti, L. Righi, F. Passiglia, S. Novello
Journal: Journal of Thoracic Oncology (2019)
P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention—Reply
Authors: Joo-Yong Hahn, Young Bin Song, Hyeon-Cheol Gwon
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue
The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma
Authors: Ling Wei, Xingwu Wang, Liyan Lv, Jibing Liu, Huaixin Xing, Yemei Song, Mengyu Xie, Tianshui Lei, Nasha Zhang, Ming Yang
Journal: Molecular Cancer (2019)

Abstract Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and the second most lethal human cancer. A portion of patients with advanced HCC can significantly benefit from treatments with sorafenib, adriamycin, 5-fluorouracil and platinum drugs. However, most HCC patients eventually develop drug resistance, resulting in a poor prognosis. The mechanisms involved in HCC drug resistance are complex and inconclusive. Human transcripts without protein-coding potential are known as noncoding RNAs (ncRNAs), including microRNAs (miRNAs), small nucleolar RNAs (snoRNAs), long noncoding RNAs (lncRNAs) and circular RNA (circRNA). Accumulated evidences demonstrate that several deregulated miRNAs and lncRNAs are important regulators in the development of HCC drug resistance which elucidates their potential clinical implications. In this review, we summarized the detailed mechanisms by which miRNAs and lncRNAs affect HCC drug resistance. Multiple tumor-specific miRNAs and lncRNAs may serve as novel therapeutic targets and prognostic biomarkers for HCC.
HLA Heterozygote Advantage against HIV-1 Is Driven by Quantitative and Qualitative Differences in HLA Allele-Specific Peptide Presentation
Authors: Jatin Arora, Federica Pierini, Paul J McLaren, Mary Carrington, Jacques Fellay, Tobias L Lenz
Journal: Molecular Biology and Evolution (2019)

Abstract Pathogen-mediated balancing selection is regarded as a key driver of host immunogenetic diversity. A hallmark for balancing selection in humans is the heterozygote advantage at genes of the human leukocyte antigen (HLA), resulting in improved HIV-1 control. However, the actual mechanism of the observed heterozygote advantage is still elusive. HLA heterozygotes may present a broader array of antigenic viral peptides to immune cells, possibly resulting in a more efficient cytotoxic T-cell response. Alternatively, heterozygosity may simply increase the chance to carry the most protective HLA alleles, as individual HLA alleles are known to differ substantially in their association with HIV-1 control. Here, we used data from 6,311 HIV-1-infected individuals to explore the relative contribution of quantitative and qualitative aspects of peptide presentation in HLA heterozygote advantage against HIV. Screening the entire HIV-1 proteome, we observed that heterozygous individuals exhibited a broader array of HIV-1 peptides presented by their HLA class I alleles. In addition, viral load was negatively correlated with the breadth of the HIV-1 peptide repertoire bound by an individual’s HLA variants, particularly at HLA-B. This suggests that heterozygote advantage at HLA-B is at least in part mediated by quantitative peptide presentation. We also observed higher HIV-1 sequence diversity among HLA-B heterozygous individuals, suggesting stronger evolutionary pressure from HLA heterozygosity. However, HLA heterozygotes were also more likely to carry certain HLA alleles, including the highly protective HLA-B*57:01 variant, indicating that HLA heterozygote advantage ultimately results from a combination of quantitative and qualitative effects in antigen presentation.
High-Level EVI1 Perturbs Hematopoietic Function By Skewing Cells Towards Myeloid Phenotype Via Induction of PU.1/ Spi1 Â Transcription
Authors: Archibald S Perkins, Michael Wilson, Edward Ayoub, Yi Zhang, McGrath E Kathleen, James Palis, Allison J. Li, Laura M. Calvi
Journal: Blood (2017)
EP1.04-07 Influence of Radiotherapy in Second-Line Treatment with Immunotherapy in Patients with Non-Small Cell Lung Cancer
Authors: E. Azkona, S. Carrera, I. Rubio, J.M. Mañe, I. Lacambra, A. Sancho, E. Novo, G. López-Vivanco
Journal: Journal of Thoracic Oncology (2019)
Helen Salisbury: Living above the shop
Authors: Helen Salisbury
Journal: BMJ (2019)

“I saw you out running the other day, doc.” Given the choice, would you prefer to work in a practice near where you live or opt for the anonymity that distance provides? Laziness won out over privacy when I joined my practice, so I live in the community I serve, and my commute is three minutes by bike.

The disadvantages are obvious: it’s harder to keep public and private personas separate. If I want to let my hair down I need to put a little distance between myself and my surgery, or I risk comments the following week about …
EP1.01-78 T4 Lung Cancer Invading the Descending Thoracic Aorta: A Case Successfully Treated with Surgery by a Multidisciplinary Team
Authors: A. De Palma, G. Nex, G. De Iaco, D. Brascia, M. Schiavone, R. Quercia, R. Pulli, D. Angiletta, G. Marulli
Journal: Journal of Thoracic Oncology (2019)
MA19.03 Differences in Symptom Burden Between Responsive and Progressive Disease in Advanced Non-Small Cell Lung Cancer (aNSCLC)
Authors: L. Williams, Q. Shi, B. El Ferjani, M. Hirschmann, D. Ponce, S. Dibaj, S. Chandwani, E. Roarty, W. Rinsurongkawong, J. Lewis, T. Burke, C. Cleeland, J. Lee, J. Roth, S. Swisher, J. Heymach, J. Zhang, G. Simon
Journal: Journal of Thoracic Oncology (2019)
EP1.14-15 Real World Clinical Experience of the Galician Lung Cancer Group: Afatinib in Patients with EGFR Positive Mutation
Authors: S. Agraso Busto, V. Varela, N. Fernandez, X.L. Firvida, L. Santome, J. Afonso, C. Azpiarte, N. De Dios Alvarez, J. Garcia, B. Campos, M.C. Areses, D. Pereiro, M. Lazaro
Journal: Journal of Thoracic Oncology (2019)
Mixed Chimerism of Bone Marrow CD34+ Sorted Cells after Matched or Haploidentical Allogeneic Stem Cell Transplantation for Myeloid Malignancies Is Predictive of Relapse
Authors: Yannick Le Bris, Audrey Menard, Thierry Guillaume, Pierre Peterlin, Alice Garnier, Amandine Le Bourgeois, Philippe Moreau, Mohamad Mohty, Marie C Bene, Patrice Chevallier
Journal: Blood (2017)
Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death
Authors: Robert W. Cross, Rong Xu, Demetrius Matassov, Stefan Hamm, Theresa E. Latham, Cheryl S. Gerardi, Rebecca M. Nowak, Joan B. Geisbert, Ayuko Ota-Setlik, Krystle N. Agans, Amara Luckay, Susan E. Witko, Lena Soukieh, Daniel J. Deer, Chad E. Mire, Heinz Feldmann, Christian Happi, Karla A. Fenton, John H. Eldridge, Thomas W. Geisbert
Journal: Journal of Clinical Investigation (2019)

Recent occurrences of filoviruses and the arenavirus Lassa virus (LASV) in overlapping endemic areas of Africa highlight the need for a prophylactic vaccine that would confer protection against all of these viruses that cause lethal hemorrhagic fever (HF). We developed a quadrivalent formulation of VesiculoVax that contains recombinant vesicular stomatitis virus (rVSV) vectors expressing filovirus glycoproteins and that also contains a rVSV vector expressing the glycoprotein of a lineage IV strain of LASV. Cynomolgus macaques were vaccinated twice with the quadrivalent formulation, followed by challenge 28 days after the boost vaccination with each of the 3 corresponding filoviruses (Ebola, Sudan, Marburg) or a heterologous contemporary lineage II strain of LASV. Serum IgG and neutralizing antibody responses specific for all 4 glycoproteins were detected in all vaccinated animals. A modest and balanced cell-mediated immune response specific for the glycoproteins was also detected in most of the vaccinated macaques. Regardless of the level of total glycoprotein-specific immune response detected after vaccination, all immunized animals were protected from disease and death following lethal challenges. These findings indicate that vaccination with attenuated rVSV vectors each expressing a single HF virus glycoprotein may provide protection against those filoviruses and LASV most commonly responsible for outbreaks of severe HF in Africa.
Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis
Authors: Toby Pillinger, Robert A McCutcheon, Luke Vano, Yuya Mizuno, Atheeshaan Arumuham, Guy Hindley, Katherine Beck, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver D Howes
Journal: The Lancet Psychiatry (2019)

Antipsychotic treatment is associated with metabolic disturbance. However, the degree to which metabolic alterations occur in treatment with different antipsychotics is unclear. Predictors of metabolic dysregulation are poorly understood and the association between metabolic change and change in psychopathology is uncertain. We aimed to compare and rank antipsychotics on the basis of their metabolic side-effects, identify physiological and demographic predictors of antipsychotic-induced metabolic dysregulation, and investigate the relationship between change in psychotic symptoms and change in metabolic parameters with antipsychotic treatment.
P1.15-02 Role of mTOR Inhibitor Everolimus in the Treatment of Metastatic Thymic Epithelial Tumors
Authors: J. Hellyer, S. Padda, S. Vali, A. Das, H. Sikora, Z. Husain, A. Kumar, T. Abbasi, H. Wakelee
Journal: Journal of Thoracic Oncology (2019)
Overexpression of the p65 Subunit of NF-kB and IkB Mediated Nuclear Sequestration of p53 as Common Events in Philadelphia Positive and Negative Chronic Myeloid Leukemia.
Authors: Alessandro Morotti, Daniela Cilloni, Riccardo Taulli, Francesca Arruga, Renata Catalano, Francesca Messa, Ilaria Defilippi, Sonia Carturan, Sara Capella, Valentina Rosso, Annalisa Chiarenza, Marisa Pautasso, Enrico Gottardi, Carola Ponzetto, Giuseppe Saglio
Journal: Blood (2005)
P1.01-120 Immune Checkpoint Inhibitors Versus Second Line Chemotherapy for Patients with Lung Cancer Refractory to First Line Chemotherapy
Authors: C. Lefebvre, E. Martin, L. Hendriks, R. Veillon, T. Filleron, F. Puisset, L. Mezquita, R. Ferrara, M. Sabatier, B. Besse, A.M. Dingemans, J. Mazieres
Journal: Journal of Thoracic Oncology (2019)
P1.13-02 Should Aortic Lymph Nodes be Considered Hilar Lymph Nodes in Patients with Completely Resected NSCLC? A Multicenter Study
Authors: N. Citak, L. Guglielmetti, Y. Aksoy, O. Isgörücü, M. Metin, A. Sayar, I. Opitz, W. Weder, I. Inci
Journal: Journal of Thoracic Oncology (2019)
Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and Sézary Syndrome (SS)
Authors: Wen-Kai Weng, Randall Armstrong, Sally Arai, Laura Johnston, Ginna G. Laport, Robert Lowsky, David B. Miklos, Judith A. Shizuru, Jonathan E. Benjamin, Robert S. Negrin, Sunil Reddy, Lynn Million, Richard T. Hoppe, Youn H. Kim
Journal: Blood (2014)
P1.14-26 ALK Fusion Variant Detection by Targeted RNA-Seq in TKIs Treated ALK-Positive Lung Adenocarcinoma
Authors: F. Tabbò, E. Gobbini, L. Muscarella, A. Rigutto, D. Trombetta, A. Bonfitto, D. Galetta, E. Maiello, O. Martelli, M. Tiseo, P. Bordi, V. Scotti, L. Ghilardi, V. Gregorc, C. Sergi, S. Pilotto, A. Del Conte, F. Cappuzzo, D. Cortinovis, G. Osman, C. Bareggi, M. Di Maio, A. Rossi, G. Rossi, E. Bria, M. Volante, G. Scagliotti, P. Graziano, S. Novello, L. Righi
Journal: Journal of Thoracic Oncology (2019)
EP1.04-26 Efficacy and Safety of Anti-PD-1 Inhibitors in Elderly Patients with Advanced Non-Small Cell Lung Cancer
Authors: Y. Tanaka, T. Okano, Y. Kudo, S. Takeuchi, Y. Makino, Y. Shimada, S. Maehara, M. Hagiwara, M. Kakihana, N. Kajiwara, T. Ohira, N. Ikeda
Journal: Journal of Thoracic Oncology (2019)
P1.14-61 EGFR Inhibitors Plus Bevacizumab Are Superior Compared to EGFR Inhibitor Monotherapy in Advanced EGFR+ NSCLC Patients with BIM Deletions
Authors: A.F. Cardona, O.G. Arrieta, A. Ruiz-Patiño, Z.L. Zatarain Barrón, L.L. Rojas, L. Corrales, C. Martin, F. Barrón, C. Sotelo, J. Rodriguez, L. Ricaurte, J. Ávila, D. Mayorga, P. Archila, J. Otero, H. Freitas, V. Cordeiro De Lima, L. Mas, H. Carranza, C. Vargas, R. Rosell
Journal: Journal of Thoracic Oncology (2019)
EP1.01-89 Retroperitoneal Metastasis with Marked Fibrosis from Lung Adenocarcinoma: An Autopsy Case Report
Authors: H. Ota, E. Narisawa, H. Chiba, H. Nakayama, Y. Tsukumo, A. Sakamoto, N. Honma, T. Ota
Journal: Journal of Thoracic Oncology (2019)